A
Ark Biotech
Develops bioreactors for the industrial production of cultivated meat
About Ark Biotech
Ark Biotech specializes in creating cost-effective bioreactors designed for the large-scale production of cultivated meat. Operating within the sustainable food technology sector, Ark Biotech serves companies aiming to produce meat through cell culture rather than traditional livestock farming. The business model revolves around the sale and deployment of bioreactors, which are essential for the industrial-scale cultivation of meat cells. Revenue is generated through the sale of these bioreactors and potentially through long-term service agreements for maintenance and support. Ark Biotech is addressing a significant market demand, with projections indicating a need for 250 million liters of bioreactor capacity by 2025 and 1 billion liters by 2030. The company is at the forefront of transforming protein consumption by providing the necessary infrastructure to scale cultivated meat production, thereby benefiting both the planet and its inhabitants.
Source: Dealroom company dataAt a glance
- Founded
- 2021
- Headquarters
- Westwood, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ark Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ark Biotech on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.